• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/10/21 9:23:27 AM ET
    $VSPR
    Business Services
    Finance
    Get the next $VSPR alert in real time by email
    SC 13G 1 filing.txt SCHEDULE 13G Amendment No. 0 VESPER HEALTHCARE ACQUISITION CORP CLASS A COMMON STOCK Cusip #92538T104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #92538T104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,465,216 Item 6: 0 Item 7: 6,068,621 Item 8: 0 Item 9: 6,068,621 Item 11: 13.192% Item 12: HC Cusip #92538T104 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 6,068,621 Item 8: 0 Item 9: 6,068,621 Item 11: 13.192% Item 12: IN Item 1(a). Name of Issuer: VESPER HEALTHCARE ACQUISITION CORP Item 1(b). Address of Issuer's Principal Executive Offices: 1345 AVENUE OF THE AMERICAS, 11TH FL NEW YORK , NY 10105 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: CLASS A COMMON STOCK Item 2(e). CUSIP Number: 92538T104 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 6,068,621 (b) Percent of Class: 13.192% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 1,465,216 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 6,068,621 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of VESPER HEALTHCARE ACQUISITION CORP. No one other person's interest in the CLASS A COMMON STOCK of VESPER HEALTHCARE ACQUISITION CORP is more than five percent of the total outstanding CLASS A COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2021 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2021, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the CLASS A COMMON STOCK of VESPER HEALTHCARE ACQUISITION CORP at January 29, 2021. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.
    Get the next $VSPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VSPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VSPR
    SEC Filings

    View All

    SEC Form 4 filed by Vesper Healthcare Acquisition Corp.

    4 - Beauty Health Co (0001818093) (Issuer)

    5/21/21 8:00:45 PM ET
    $VSPR
    Business Services
    Finance

    SEC Form 4 filed by Vesper Healthcare Acquisition Corp.

    4 - Beauty Health Co (0001818093) (Issuer)

    5/21/21 7:59:07 PM ET
    $VSPR
    Business Services
    Finance

    SEC Form 8-K filed by Vesper Healthcare Acquisition Corp.

    8-K - Beauty Health Co (0001818093) (Filer)

    5/20/21 4:07:22 PM ET
    $VSPR
    Business Services
    Finance

    $VSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Woo Liyuan

    4 - Beauty Health Co (0001818093) (Issuer)

    5/21/21 8:00:17 PM ET
    $VSPR
    Business Services
    Finance

    SEC Form 4 filed by LCP Edge Holdco LLC

    4 - Beauty Health Co (0001818093) (Issuer)

    5/21/21 4:34:28 PM ET
    $VSPR
    Business Services
    Finance

    SEC Form 4 filed by SAUNDERS BRENT L

    4 - Beauty Health Co (0001818093) (Issuer)

    5/18/21 9:22:28 PM ET
    $VSPR
    Business Services
    Finance

    $VSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson initiated coverage on Vesper Healthcare Acquisition Corp. with a new price target

    DA Davidson initiated coverage of Vesper Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $15.50

    4/13/21 6:59:11 AM ET
    $VSPR
    Business Services
    Finance

    The Benchmark Company initiated coverage on Vesper Healthcare Acquisition Corp. with a new price target

    The Benchmark Company initiated coverage of Vesper Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $16.00

    3/18/21 7:41:55 AM ET
    $VSPR
    Business Services
    Finance

    Benchmark initiated coverage on Vesper Healthcare with a new price target

    Benchmark initiated coverage of Vesper Healthcare with a rating of Buy and set a new price target of $16.00

    3/18/21 6:57:43 AM ET
    $VSPR
    Business Services
    Finance

    $VSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Linden and DW Healthcare Partners Complete HydraFacial's Public Offering via SPAC Merger

    CHICAGO and PARK CITY, Utah, May 5, 2021 /PRNewswire/ -- Linden Capital Partners ("Linden") and DW Healthcare Partners IV, LP ("DW Healthcare Partners"), both private equity firms focused exclusively on the healthcare sector, announced today the completion of the merger of Edge Systems, LLC ("HydraFacial"), a category-creating beauty health company, with Vesper Healthcare Acquisition Corp. (NASDAQ:VSPR) ("Vesper" or "Vesper Healthcare"). Vesper is a special purpose acquisition company ("SPAC") led by former Allergan CEO Brent Saunders. As a result of the transaction, the combined company, now known as The Beauty Health Company ("BeautyHealth" or the "Company"), is expected to trade on the Na

    5/5/21 7:30:00 AM ET
    $VSPR
    Business Services
    Finance

    HydraFacial Announces Record First Quarter Fiscal 2021 Preliminary Net Sales

    First Quarter 2021 Preliminary Financial Highlights: Q1 net sales of $47 million compared to $33 million in Q1 2020 and $35 million in Q1 2019 Q1 net sales in the Americas region of $31 million, or 66% of total net sales, compared to $24 million in Q1 2020 and $27 million in Q1 2019 Q1 net sales in the EMEA and APAC regions of $16 million, or 34% of total sales, compared to $9 million in Q1 2020 and $8 million in Q1 2019 The HydraFacial® Company ("HydraFacial," or the "Company"), an experiential category-creating beauty health company, today announced preliminary net sales for the quarter ended March 31, 2021. The Company has not yet completed the quarter-end review and expects to r

    4/21/21 6:45:00 AM ET
    $VSPR
    Business Services
    Finance

    HydraFacial, a Beauty Health Company, Announces 2020 Preliminary Net Sales

    MIAMI BEACH, Fla. & LONG BEACH, Calif.--(BUSINESS WIRE)--The HydraFacial® Company (“HydraFacial,” or the “Company”), a category-creating beauty health company, today announced preliminary net sales for the fiscal year ended December 31, 2020. HydraFacial currently expects net sales for fiscal year 2020 to approximate $119 million. The Company’s previous expectation for net sales, provided on December 9, 2020, was approximately $115 million. The Company has not yet completed the year-end audit and expects to report full results for fiscal year 2020 at a future date. The previously announced business combination with Vesper Healthcare (NASDAQ: VSPR) remains on track to be completed

    2/22/21 6:45:00 AM ET
    $VSPR
    Business Services
    Finance

    $VSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Vesper Healthcare Acquisition Corp. (Amendment)

    SC 13D/A - Beauty Health Co (0001818093) (Subject)

    5/21/21 4:30:37 PM ET
    $VSPR
    Business Services
    Finance

    SEC Form SC 13D filed by Vesper Healthcare Acquisition Corp.

    SC 13D - Beauty Health Co (0001818093) (Subject)

    5/14/21 4:23:32 PM ET
    $VSPR
    Business Services
    Finance

    SEC Form SC 13G filed

    SC 13G - Vesper Healthcare Acquisition Corp. (0001818093) (Subject)

    2/16/21 3:58:03 PM ET
    $VSPR
    Business Services
    Finance